I'm here to tell you the bull case for Lilly’s Foundayo rests on an unspoken assumption: nobody in the target demographic is having sex. Sounds crazy? The facts: Oral Wegovy seems to be more effective than Foundayo. ~14% vs ~11% weight loss at max dose in a cross-trial comparison.[1] The injectable GLP-1 market is kinda old people. These are postmenopausal women and middle-aged dudes with metabolic syndrome. They signed up for needles, cold chain, and insurance fights. They have demonstrated they don't give a shit about friction. The pill market is different. Younger. Lower BMI. Price-sensitive. Needle-averse. Convenience-maximalist. This is where Foundayo's growth has to come from. Here's the kicker I suspect nobody is pricing in. Foundayo's FDA label requires women on oral birth control to either switch to non-oral contraception OR use condoms for 30 days after starting AND 30 days after each dose escalation.…